Stock Research: JCR Pharmaceuticals

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

JCR Pharmaceuticals

TSE:4552 JP3701000006
8
  • Value
    38
  • Growth
    56
  • Safety
    Safety
    6
  • Combined
    12
  • Sentiment
    6
  • 360° View
    360° View
    8
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

JCR Pharmaceuticals Co., Ltd. is a Japan-based company primarily engaged in the pharmaceutical business and the medical and research equipment business. The company operates in two segments: the Pharmaceutical segment (research, production, purchase, and sale of medical drugs and pharmaceutical raw materials) and the Medical and Research Equipment segment (purchase and sale of medical and research equipment). It primarily operates in Japan. In the last fiscal year, the company had 987 employees, a market cap of $598 million, profits of $145 million, and revenue of $221 million.

more
Index
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 8-Jan-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
38 74 34 25
Growth
56 4 27 73
Safety
Safety
6 41 57 28
Sentiment
6 1 57 31
360° View
360° View
8 4 36 21
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
5 28 41 44
Opinions Change
50 21 69 50
Pro Holdings
n/a 1 84 30
Market Pulse
21 13 33 51
Sentiment
6 1 57 31
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
38 74 34 25
Growth
56 4 27 73
Safety Safety
6 41 57 28
Combined
12 18 31 39
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
39 54 32 20
Price vs. Earnings (P/E)
29 53 49 47
Price vs. Book (P/B)
44 69 38 16
Dividend Yield
83 84 51 34
Value
38 74 34 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
22 6 6 4
Profit Growth
84 9 85 91
Capital Growth
37 7 51 94
Stock Returns
74 6 11 39
Growth
56 4 27 73
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
9 25 25 20
Refinancing
32 41 49 17
Liquidity
4 67 84 82
Safety Safety
6 41 57 28

Similar Stocks

Discover high‑ranked alternatives to JCR Pharmaceuticals and broaden your portfolio horizons.

Japan Airlines

TSE:9201
Country: Japan
Industry: Airlines
Size: X-Large
Full Stock Analysis

Alfresa Holdings

TSE:2784
Country: Japan
Industry: Health Care Distributors
Size: Large
Full Stock Analysis

Sankyu

TSE:9065
Country: Japan
Industry: Trucking
Size: Medium
Full Stock Analysis

Kumagai Gumi

TSE:1861
Country: Japan
Industry: Construction & Engineering
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

The only positive is high growth. The stock is expensive (low Value Rank), risky to finance, and carries critical professional sentiment. This is a risky proposition. Avoid unless you have exceptional conviction that the growth alone will overcome the price and financial risks.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: